Repositioning Candidate Details
Candidate ID: | R1585 |
Source ID: | DB15868 |
Source Type: | investigational |
Compound Type: | biotech |
Compound Name: | Amniotic Epithelial Cells |
Synonyms: | hAECs; Human Amniotic Epithelial Cells |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication. |
CAS Number: | -- |
Molecular Weight: | |
DrugBank Indication: | -- |
DrugBank Pharmacology: | -- |
DrugBank MoA: | Amniotic epithelial cells have immunosuppression properties, the likely reason why these cells seem to be resistant to rejection after allotransplantation. Further therapeutic effects of these cells include reported neuroprotection and neuroregeneration properties, attributed to the growth factor secretion by AECs. These cells are being investigated as a therapy against many different conditions, some of which include lung fibrosis, liver fibrosis, multiple sclerosis, congenital metabolic disorders, familial hypercholesterolemia, spinal cord injuries, ophthalmic diseases, and Parkinson’s disease. |
Targets: | -- |
Inclusion Criteria: | Therapeutic strategy associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
S15 | Cell therapy | Mesenchymal stem cells; Stem cell therapy | -- | -- | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|